이상반응 보고

VAERS ID	2594254
성별	남성
나이	54세
주 코드	FR
제약회사	PFIZER\BIONTECH
로트 번호	GL8592
예방접종 횟수	5
접종일	2022-12-05
발병일	2022-12-01
상태	입원 후유증

증상

이환 중 질병

지병

기타 의료

이전 예방접종

알레르기

임상 검사

Test Name: test result for anti GFAP antibody; Test Result: Positive ; Test Date: 20221221; Test Name: MRI; Result Unstructured Data: Test Result:extensive lesions in the central nervous system; Comments: extensive lesions in the central nervous system including the cerebrum, the cerebellum, the brain stem and the spinal cord.

증상 상세

This is a spontaneous report received from a contactable reporter(s) (Physician) from Regulatory Authority.
Regulatory number: v2210003959 (PMDA).
A 54-years and 4-months-old male patient received BNT162b2, BNT162b2 omi ba.
4-5 (COMIRNATY RTU FOR BA.
4-5), on 05Dec2022 as dose 5 (booster), single (Lot number: GL8592, Expiration Date: 31Aug2023) at the age of 54 years for covid-19 immunisation.
The patient's relevant medical history and concomitant medications were not reported.
Vaccination history included: Comirnaty (DOSE 1, single), for Covid-19 immunisation; Comirnaty (DOSE 2, single), for Covid-19 immunisation; Comirnaty (DOSE 3, single), for Covid-19 immunisation; Comirnaty (DOSE 4, single), for Covid-19 immunisation.
The patient experienced pyrexia on 06Dec2022; on 12Dec2022, consciousness disturbed/severe consciousness disturbed was prolonged/consciousness disturbed with JCS3-300 was prolonged was noted; ACUTE DISSEMINATED ENCEPHALOMYELITIS (ADEM ) in Dec2022; encephalitis in Dec2022; encephalitis autoimmune/a positive test result for anti GFAP antibody was proven and autoimmune GFAP astrocytopathy was diagnosed in Dec2022; encephalopathy in Dec2022; orientation disturbed in Dec2022; extensive lesions in the central nervous system including the cerebrum, the cerebellum, the brain stem and the spinal cord in Dec2022.
The reporting physician commented that although the causal relation with the vaccination could not be determined, the event developed on the next day of the vaccination.
Hence the case was considered to be reportable according to ADEM, encephalitis, or encephalopathy.
The report met the criteria of encephalopathy and encephalitis.